Erschienen in:

22.08.2024 | Sarcoma

Histology-Tailored Approach to Soft Tissue Sarcoma

verfasst von: Mai-Kim Gervais, MD, Georges Basile, MD, Jean-Philippe Dulude, MD, Sophie Mottard, MD, Alessandro Gronchi, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 12/2024

Einloggen, um Zugang zu erhalten

Abstract

Soft tissue sarcomas are a diverse and heterogeneous group of cancers of mesenchymal origin. Each histological type of soft tissue sarcoma has unique clinical particularities, which makes them challenging to diagnose and treat. Multidisciplinary management of these rare diseases is thus key for improved survival. The role of surgery has been well established, and it represents the cornerstone curative treatment for soft tissue sarcomas. To date, local recurrence is the leading cause of death in low-grade sarcomas located at critical sites, and distant metastasis in high-grade sarcomas, regardless of the site of origin. Management must be tailored to each individual histologic type. We describe the most common types of extremity, trunk, abdominal, and retroperitoneal soft tissue sarcoma along with characteristics to consider for optimized management.

Gatta G, van der Zwan JM, Casali PG, et al. RARECARE working group. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer. 2011;47:2493–511.PubMedCrossRef

Brennan MFSS, Maki RG, O’Sullivan B. Sarcomas of the soft tissue and bone. In: VT Devita Jr, SL Theodore, SA Rosenberg, editors. Cancer—Principles and Practice of Oncology. 8th edn. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 1741–93.

WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. Lyon (France): International Agency for Research on Cancer; 2020. (WHO classification of tumours series, 5th ed. Vol. 3). https://publications.Iarc.fr/588

Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2017, National Cancer Institute. Betherda, MD https://seer.cancer.gov/csr/1975_2017/

Callegaro D, Miceli R, Bonvalot S, et al. Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localized soft-tissue sarcomas of the extremities: a retrospective analysis. Lancet Oncol. 2016;17:671–80.PubMedCrossRef

von Mehren M, Randall RL, Benjamin RS, et al. Soft tissue sarcoma, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016;14:758–86.CrossRef

ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):102–12.

Pasquali S, Pizzamiglio S, Touati N, et al. The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. Eur J Cancer. 2019;109:51–60.PubMedCrossRef

Pasquali S, Palmerini E, Quagliuolo V, et al. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: a Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial. Cancer. 2022;128(1):85–93.PubMedCrossRef

10.

Lambdin J, Ryan C, Gregory S, et al. A randomized phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with high-risk retroperitoneal sarcoma (STRASS2). Ann Surg Oncol. 2023;30(8):4573–5.PubMedPubMedCentralCrossRef

11.

Gronchi A, Colombo C, Raut CP. Surgical management of localized soft tissue tumors. Cancer. 2014;120:2638–48.PubMedCrossRef

12.

Weiss SW. Lipomatous tumors. Monogr Pathol. 1996;38:207–39.PubMed

13.

Nishio J, Nakayama S, Chijiiwa Y, Aoki M. Biology and management of deep-seated atypical lipomatous tumor of the extremities. Anticancer Res. 2023;43(10):4295–301. https://doi.org/10.21873/anticanres.16624.CrossRefPubMed

14.

Choi KY, Jost E, Mack L, Bouchard-Fortier A. Surgical management of truncal and extremities atypical lipomatous tumors/well-differentiated liposarcoma: A systematic review of the literature. Am J Surg. 2020;219(5):823–7. https://doi.org/10.1016/j.amjsurg.2020.01.046.CrossRefPubMed

15.

Rauh J, Klein A, Baur-Melnyk A, et al. The role of surgical margins in atypical Lipomatous Tumours of the extremities. BMC Musculoskeletal Disorders. 2018;19(1):152. https://doi.org/10.1186/s12891-018-2053-3.CrossRefPubMedPubMedCentral

16.

Kito M, Yoshimura Y, Isobe K, et al. Clinical outcome of deep-seated atypical lipomatous tumor of the extremities with median-term follow-up study. Eur J Surg Oncol. 2015;41(3):400–6. https://doi.org/10.1016/j.ejso.2014.11.044.CrossRefPubMed

17.

Vos M, Grünhagen DJ, Koseła-Paterczyk H, Rutkowski P, Sleijfer S, Verhoef C. Natural history of well-differentiated liposarcoma of the extremity compared to patients treated with surgery. Surg Oncol. 2019;29:84–9. https://doi.org/10.1016/j.suronc.2019.04.004.CrossRefPubMed

18.

Kido A, Kitagawa Y, Tsukushi S, et al. Marginal resection for patients with atypical lipomatous tumours of the extremities and trunk wall: a systematic review and meta-analysis. Jpn J Clin Oncol. 2022;52(2):151–6. https://doi.org/10.1093/jjco/hyab185.CrossRefPubMed

19.

Tfayli Y, Baydoun A, Naja AS, Saghieh S. Management of myxoid liposarcoma of the extremity. Oncol Lett. 2021;22(2):596. https://doi.org/10.3892/ol.2021.12857.CrossRefPubMedPubMedCentral

20.

Chowdhry V, Goldberg S, DeLaney TF, et al. Myxoid liposarcoma: treatment outcomes from chemotherapy and radiation therapy. Sarcoma. 2018;2018:8029157. https://doi.org/10.1155/2018/8029157.CrossRefPubMedPubMedCentral

21.

Dürr HR, Rauh J, Baur-Melnyk A, et al. Myxoid liposarcoma: local relapse and metastatic pattern in 43 patients. BMC Cancer. 2018;18(1):304. https://doi.org/10.1186/s12885-018-4226-8.CrossRefPubMedPubMedCentral

22.

Lansu JTP. Less Is More: Towards a Tailored Approach in Myxoid Liposarcoma. Leiden University; 2022. Accessed April 28, 2024. https://hdl.handle.net/1887/3264364

23.

Muratori F, Greto D, Cenatiempo M, et al. Leiomyosarcoma: clinicopathological study and retrospective analysis of prognostic factors in a series of 100 patients. J Orthop. 2019;16(4):303–7. https://doi.org/10.1016/j.jor.2019.03.004.CrossRefPubMedPubMedCentral

24.

Yu JI. Myxoid liposarcoma: a well-defined clinical target variant in radiotherapy for soft tissue sarcoma. Radiat Oncol J. 2022;40(4):213–5. https://doi.org/10.3857/roj.2022.00598.CrossRefPubMedPubMedCentral

25.

Muratori F, Bettini L, Frenos F, et al. Myxoid liposarcoma: prognostic factors and metastatic pattern in a series of 148 patients treated at a single institution. Int J Surg Oncol. 2018;2018:8928706. https://doi.org/10.1155/2018/8928706.CrossRefPubMedPubMedCentral

26.

Visgauss JD, Wilson DA, Perrin DL, et al. Staging and surveillance of myxoid liposarcoma: follow-up assessment and the metastatic pattern of 169 patients suggests inadequacy of current practice standards. Ann Surg Oncol. 2021;28(12):7903–11. https://doi.org/10.1245/s10434-021-10091-1.CrossRefPubMed

27.

Stevenson JD, Watson JJ, Cool P, et al. Whole-body magnetic resonance imaging in myxoid liposarcoma: A useful adjunct for the detection of extra-pulmonary metastatic disease. Eur J Surg Oncol. 2016;42(4):574–80. https://doi.org/10.1016/j.ejso.2015.12.011.CrossRefPubMed

28.

Pitson G, Robinson P, Wilke D, et al. Radiation response: an additional unique signature of myxoid liposarcoma. Int J Radiat Oncol Biol Phys. 2004;60(2):522–6. https://doi.org/10.1016/j.ijrobp.2004.03.009.CrossRefPubMed

29.

Engström K, Bergh P, Cederlund CG, et al. Irradiation of myxoid/round cell liposarcoma induces volume reduction and lipoma-like morphology. Acta Oncol. 2007;46(6):838–45. https://doi.org/10.1080/02841860601080415.CrossRefPubMed

30.

Betgen A, Haas RLM, Sonke JJ. Volume changes in soft tissue sarcomas during preoperative radiotherapy of extremities evaluated using cone-beam CT. J Radiat Oncol. 2013;2(1):55–62. https://doi.org/10.1007/s13566-012-0085-0.CrossRefPubMedPubMedCentral

31.

Hatano H, Ogose A, Hotta T, et al. Treatment of myxoid liposarcoma by marginal or intralesional resection combined with radiotherapy. Anticancer Res. 2003;23(3C):3045–9.PubMed

32.

Perera JR, AlFaraidy M, Ibe I, et al. Intermuscular extremity myxoid liposarcoma can be managed by marginal resection following neoadjuvant radiotherapy. Eur J Surg Oncol. 2023;49(2):362–7. https://doi.org/10.1016/j.ejso.2022.09.008.CrossRefPubMed

33.

Lansu J, Bovée JVM, Braam P, et al. Dose reduction of preoperative radiotherapy in mixoid liposarcoma: a nonrandomized controlled trial. JAMA Oncol. 2021;7(1):e205865. https://doi.org/10.1001/jamaoncol.2020.5865.CrossRefPubMed

34.

Patel SR, Burgess MA, Plager C, Papadopoulos NE, Linke KA, Benjamin RS. Myxoid liposarcoma. Experience with chemotherapy. Cancer. 1994;74(4):1265–9. https://doi.org/10.1002/1097-0142(19940815)74:4%3c1265::aid-cncr2820740414%3e3.0.co;2-x.CrossRefPubMed

35.

Gronchi A, Palmerini E, Quagliulo V, et al. Neoadjuvant chemotherapy in high-grade myxoid liposarcoma: results of the expanded cohort of a randomized trial from Italian (ISG), Spanish (GEIS), French (FSG), and Polish sarcoma groups (PSG). J Clin Oncol. 2024;42:898–906.PubMedCrossRef

36.

Gronchi A, Hindi N, Cruz J, et al. Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): results of a phase I study in myxoid liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups. EClinicalMedicine. 2019;9:35–43. https://doi.org/10.1016/j.eclinm.2019.03.007.CrossRefPubMedPubMedCentral

37.

Sun H, Liu J, Hu F, et al. Current research and management of undifferentiated pleomorphic sarcoma/myxofibrosarcoma. Front Genet. 2023;14:1109491. https://doi.org/10.3389/fgene.2023.1109491.CrossRefPubMedPubMedCentral

38.

Bleckman RF, Acem I, Praag VMV, et al. Multimodality treatment of undifferentiated pleomorphic soft tissue sarcoma of the extremity (eUPS) in the elderly. Eur J Surg Oncol. 2022;48:985–93.PubMedCrossRef

39.

Woll PJ, Reichardt P, Le Cesne A, et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol. 2012;13:1045–54.PubMedCrossRef

40.

Gronchi A, Frustaci S, Mercuri M, et al. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. J Clin Oncol. 2012;30:850–6.PubMedCrossRef

41.

Gronchi A, Ferrari S, Quagliuolo V, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomized, controlled, phase 3, multicentre trial. Lancet Oncol. 2017;18:812–22.PubMedCrossRef

42.

Gronchi A, Palmerini E, Quagliuolo V, et al. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: final results of a randomized trial from Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. J Clin Oncol. 2020;38(19):2178–86.PubMedCrossRef

43.

Mowery YM, Ballman KV, Hong AM, et al. Radiation therapy and pembrolizumab in soft tissue sarcoma of the extremity. ASCO abstract 2024

44.

Mowery WM, Ballman KV, Riedel RF, et al. SU2C-SARC032: a phase II randomized controlled trial of neoadjuvant pembrolizumab with radiotherapy and adjuvant pembrolizumab for high-risk soft tissue sarcoma. J Clin Oncol. 2018. https://doi.org/10.1200/JCO.2018.36.15_suppl.TPS11588.CrossRef

45.

Keung EZ, Lazar AJ, Torres KE, et al. Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. BMC Cancer. 2018;18(1):913. https://doi.org/10.1186/s12885-018-4829-0.CrossRefPubMedPubMedCentral

46.

Roland CL, Nassif Haddad EF, Keung EZ, et al. A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dediffentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma. Nat Cancer. 2024. https://doi.org/10.1038/s43018-024-00726-z.CrossRefPubMed

47.

Danieli M, Barretta F, Radaelli S, et al. Pathological and radiological response following neoadjuvant treatments in primary localized resectable myxofibrosarcoma and undifferentiated pleomorphic sarcoma of the extremities and trunk wall. Cancer. 2023;129:3417–29.PubMedCrossRef

48.

Hu Q, Zhou S, Hu X, Zhang H, Huang S, Wang Y. Systematic screening identifies a 2-gene signature as a high-potential prognostic marker of undifferentiated pleomorphic sarcoma/myxofibrosarcoma. J Cell Mol Med. 2020;24(1):1010–21. https://doi.org/10.1111/jcmm.14814.CrossRefPubMed

49.

Welsch K, Breuninger H, Metzler G, et al. Patterns of infiltration and local recurrences of various types of cutaneous sarcomas following three-dimensional histology. J Ger Soc Dermatol JDDG. 2018;16:1434–42. https://doi.org/10.1111/ddg.13708.CrossRef

50.

Fujiwara T, Sumathi V, Parry M, et al. The role of surgical margin quality in myxofibrosarcoma and undifferentiated pleomorphic sarcoma. Eur J Surg Oncol. 2021;47:1756–62.PubMedCrossRef

51.

Crago AM, Cardona K, Kosela-Paterczyk H, Rutkowski P. Management of myxofibrosarcoma and undifferentiated pleomorphic sarcoma. Surg Oncol Clin N Am. 2023;31:419–30.CrossRef

52.

Cable MG, Randall RL. Extremity soft tissue sarcoma: tailoring resection to histologic subtype. Surg Oncol Clin N Am. 2016;25(4):677–95. https://doi.org/10.1016/j.soc.2016.05.014.CrossRefPubMed

53.

Kannan S, Chong HH, Chew B, et al. Leiomyosarcoma in the extremities and trunk wall: systematic review and meta-analysis of the oncological outcomes. World J Surg Oncol. 2022;20:124. https://doi.org/10.1186/s12957-022-02584-4.CrossRefPubMedPubMedCentral

54.

Worhunsky DJ, Gupta M, Gholami S, et al. Leiomyosarcoma: One disease or distinct biologic entities based on site of origin? J Surg Oncol. 2015;111(7):808–12. https://doi.org/10.1002/jso.23904.CrossRefPubMed

55.

Coindre JM, Terrier P, Bui NB, et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol. 1996;14(3):869–77. https://doi.org/10.1200/JCO.1996.14.3.869.CrossRefPubMed

56.

van Beeck A, van de Sande M, van Praag V, et al. Clinical outcome of surgically treated leiomyosarcoma of the extremities: a retrospective overview. Anticancer Res. 2020;40(9):5319–25. https://doi.org/10.21873/anticanres.14539.CrossRefPubMed

57.

Gustafson P, Willén H, Baldetorp B, Fernö M, Akerman M, Rydholm A. Soft tissue leiomyosarcoma. A population-based epidemiologic and prognostic study of 48 patients, including cellular DNA content. Cancer. 1992;70(1):114–9. https://doi.org/10.1002/1097-0142(19920701)70:1%3c114::aid-cncr2820700119%3e3.0.co;2-u.CrossRefPubMed

58.

Neugut AL, Sordillo PP. Leiomyosarcomas of the extremities. J Surg Oncol. 1989;40(1):65–7. https://doi.org/10.1002/jso.2930400115.CrossRefPubMed

59.

D’Ambrosio L, Touati N, Blay JY, et al. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: a propensity score matching analysis from the European Organization for research and treatment of cancer soft tissue and bone sarcoma group. Cancer. 2020;126:2637–47.PubMedCrossRef

60.

Pautier P, Italiano A, Piperno-Neumann S, et al. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised multicentre, open-label phase 3 trial. Lancet Oncol. 2022;23:1044–54.PubMedCrossRef

61.

Blay JY, von Mehren M, Jones RL, et al. Synovial sarcoma: characteristics, challenges, and evolving therapeutic strategies. ESMO Open. 2023;8(5):101618. https://doi.org/10.1016/j.esmoop.2023.101618.CrossRefPubMedPubMedCentral

62.

Stacchiotti S, Van Tine BA. Synovial sarcoma: current concepts and future perspectives. J Clin Oncol. 2018;36(2):180–7. https://doi.org/10.1200/JCO.2017.75.1941.CrossRefPubMed

63.

Vlenterie M, Litière S, Rizzo E, et al. Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity. Eur J Cancer. 2016;58:62–72. https://doi.org/10.1016/j.ejca.2016.02.002.CrossRefPubMed

64.

Ferrari A, De Salvo GL, Brennan B, et al. Synovial sarcoma in children and adolescents: the European Pediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005). Ann Oncol. 2015;26(3):567–72. https://doi.org/10.1093/annonc/mdu562.CrossRefPubMed

65.

Riedel RF, Jones RL, Italiano A, et al. Systemic anti-cancer therapy in synovial sarcoma: a systematic review. Cancers. 2018;10(11):417. https://doi.org/10.3390/cancers10110417.CrossRefPubMedPubMedCentral

66.

Faur C, Pop D, Abu-Awwad A, et al. Synovial sarcoma of the extremities: a literature review. Appl Sci. 2021;11:7407. https://doi.org/10.3390/app11167407.CrossRef

67.

Li C, Krasniqi F, Donners R, Kettelhack C, Krieg AH. Synovial sarcoma: the misdiagnosed sarcoma. EFORT Open Rev. 2024;9(3):190–201. https://doi.org/10.1530/EOR-23-0193.CrossRefPubMedPubMedCentral

68.

Weingrad DN, Rosenberg SA. Early lymphatic spread of osteogenic and soft-tissue sarcomas. Surgery. 1978;84(2):231–40.PubMed

69.

Mazeron JJ, Suit HD. Lymph nodes as sites of metastases from sarcomas of soft tissue. Cancer. 1987;60(8):1800–8.PubMedCrossRef

70.

Basile G, Mattei JC, Alshaygy I, et al. Curability of patients with lymph node metastases from extremity soft-tissue sarcoma. Cancer. 2020;126(23):5098–108. https://doi.org/10.1002/cncr.33189.CrossRefPubMed

71.

Jacobs AJ, Morris CD, Levin AS. Synovial sarcoma is not associated with a higher risk of lymph node metastasis compared with other soft tissue sarcomas. Clin Orthop Relat Res. 2018;476(3):589–98. https://doi.org/10.1007/s11999.0000000000000057.CrossRefPubMedPubMedCentral

72.

Murphey MD, Gibson MS, Jennings BT, Crespo-Rodríguez AM, Fanburg-Smith J, Gajewski DA. From the archives of the AFIP: Imaging of synovial sarcoma with radiologic-pathologic correlation. Radiographics. 2006;26(5):1543–65. https://doi.org/10.1148/rg.265065084.CrossRefPubMed

73.

Blacksin MF, Siegel JR, Benevenia J, Aisner SC. Synovial sarcoma: frequency of nonaggressive MR characteristics. J Comput Assist Tomogr. 1997;21(5):785–9. https://doi.org/10.1097/00004728-199709000-00025.CrossRefPubMed

74.

Wang DJ, Alwafi L, Pritchett SL, Wehrli BM, Spouge ARI. The imaging spectrum of synovial sarcomas: a pictorial review from a single-centre tertiary referral institution. Can Assoc Radiol J. 2021;72(3):470–82. https://doi.org/10.1177/0846537119899284.CrossRefPubMed

75.

Song S, Park J, Kim HJ, et al. Effects of adjuvant radiotherapy in patients with synovial sarcoma. Am J Clin Oncol. 2017;40(3):306. https://doi.org/10.1097/COC.0000000000000148.CrossRefPubMed

76.

Gronchi A, Miah AB, Dei Tos AP, et al. Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Ann Oncol. 2021;32(11):1348–65. https://doi.org/10.1016/j.annonc.2021.07.006.CrossRefPubMed

77.

Sleijfer S, Ouali M, van Glabbeke M, et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer. 2010;46(1):72–83. https://doi.org/10.1016/j.ejca.2009.09.022.CrossRefPubMed

78.

Ferrari A, Chi YY, De Salvo GL, et al. Surgery alone is sufficient therapy for children and adolescents with low-risk synovial sarcoma: A joint analysis from the European paediatric soft tissue sarcoma Study Group and the Children’s Oncology Group. Eur J Cancer. 2017;78:1–6. https://doi.org/10.1016/j.ejca.2017.03.003.CrossRefPubMedPubMedCentral

79.

Canter RJ, Qin LX, Maki RG, Brennan MF, Ladanyi M, Singer S. A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. Clin Cancer Res. 2008;14(24):8191–7. https://doi.org/10.1158/1078-0432.CCR-08-0843.CrossRefPubMedPubMedCentral

80.

Pan M, Merchant M. Risk factors including age, stage and anatomic location that impact the outcomes of patients with synovial sarcoma. Med Sci (Basel). 2018;6(1):21. https://doi.org/10.3390/medsci6010021.CrossRefPubMed

81.

Xu G, Aiba H, Yamamoto N, et al. Efficacy of perioperative chemotherapy for synovial sarcoma: a retrospective analysis of a Nationwide database in Japan. BMC Cancer. 2021;21(1):773. https://doi.org/10.1186/s12885-021-08485-1.CrossRefPubMedPubMedCentral

82.

Goertz O, Langer S, Uthoff D, et al. Diagnosis, treatment and survival of 65 patients with malignant peripheral nerve sheath tumors. Anticancer Res. 2014;34(2):777–83.PubMed

83.

Cai Z, Tang X, Liang H, Yang R, Yan T, Guo W. Prognosis and risk factors for malignant peripheral nerve sheath tumor: a systematic review and meta-analysis. World J Surg Oncol. 2020;18(1):257. https://doi.org/10.1186/s12957-020-02036-x.CrossRefPubMedPubMedCentral

84.

James AW, Shurell E, Singh A, Dry SM, Eilber FC. Malignant peripheral nerve sheath tumor. Surg Oncol Clin N Am. 2016;25(4):789–802. https://doi.org/10.1016/j.soc.2016.05.009.CrossRefPubMed

85.

Katz D, Lazar A, Lev D. Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways. Expert Rev Mol Med. 2009;11:e30. https://doi.org/10.1017/S1462399409001227.CrossRefPubMed

86.

Knight SWE, Knight TE, Santiago T, Murphy AJ, Abdelhafeez AH. Malignant Peripheral nerve sheath tumors—a comprehensive review of pathophysiology, diagnosis, and multidisciplinary management. Children. 2022;9(1):38. https://doi.org/10.3390/children9010038.CrossRefPubMedPubMedCentral

87.

Derlin T, Tornquist K, Münster S, et al. Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Clin Nucl Med. 2013;38(1):e19-25. https://doi.org/10.1097/RLU.0b013e318266ce84.CrossRefPubMed

88.

Sharma MR, Puj KS, Salunke AA, Pandya SJ, Gandhi JS, Parikh AR. Malignant peripheral nerve sheath tumor with analysis of various prognostic factors: a single-institutional experience. J Cancer Res Therapeutics. 2021;17(1):106. https://doi.org/10.4103/jcrt.JCRT_854_19.CrossRef

89.

Sharif S, Ferner R, Birch JM, et al. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol. 2006;24(16):2570–5. https://doi.org/10.1200/JCO.2005.03.8349.CrossRefPubMed

90.

Kahn J, Gillespie A, Tsokos M, et al. Radiation therapy in management of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Front Oncol. 2014;4:324. https://doi.org/10.3389/fonc.2014.00324.CrossRefPubMedPubMedCentral

91.

Farid M, Demicco EG, Garcia R, et al. Malignant peripheral nerve sheath tumors. Oncologist. 2014;19(2):193–201. https://doi.org/10.1634/theoncologist.2013-0328.CrossRefPubMedPubMedCentral

92.

Zou C, Smith KD, Liu J, et al. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg. 2009;249(6):1014–22. https://doi.org/10.1097/SLA.0b013e3181a77e9a.CrossRefPubMed

93.

Stucky CCH, Johnson KN, Gray RJ, et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann Surg Oncol. 2012;19(3):878–85. https://doi.org/10.1245/s10434-011-1978-7.CrossRefPubMed

94.

Amirian ES, Goodman JC, New P, Scheurer ME. Pediatric and adult malignant peripheral nerve sheath tumors: an analysis of data from the surveillance, epidemiology, and end results program. J Neurooncol. 2014;116(3):609–16. https://doi.org/10.1007/s11060-013-1345-6.CrossRefPubMed

95.

Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ. Angiosarcoma. Lancet Oncol. 2010;11(10):983–91. https://doi.org/10.1016/S1470-2045(10)70023-1.CrossRefPubMed

96.

Shen CJ, Parzuchowski AS, Kummerlowe MN, et al. Combined modality therapy improves overall survival for angiosarcoma. Acta Oncol. 2017;56(9):1235–8. https://doi.org/10.1080/0284186X.2017.1306104.CrossRefPubMed

97.

Shon W, Billings SD. Cutaneous Malignant Vascular Neoplasms. Clin Lab Med. 2017;37(3):633–46. https://doi.org/10.1016/j.cll.2017.06.004.CrossRefPubMed

98.

Shustef E, Kazlouskaya V, Prieto VG, Ivan D, Aung PP. Cutaneous angiosarcoma: a current update. J Clin Pathol. 2017;70(11):917–25. https://doi.org/10.1136/jclinpath-2017-204601.CrossRefPubMed

99.

Cao J, Wang J, He C, Fang M. Angiosarcoma: a review of diagnosis and current treatment. Am J Cancer Res. 2019;9(11):2303–13.PubMedPubMedCentral

100.

Schott I, Liffers ST, Farzaliyev F, et al. Localized angiosarcoma, not one disease: a retrospective single-center study on prognosis depending on the primary site and etiology. Sarcoma. 2021;2021:9960085. https://doi.org/10.1155/2021/9960085.CrossRefPubMedPubMedCentral

101.

Mark RJ, Poen JC, Tran LM, Fu YS, Juillard GF. Angiosarcoma. A report of 67 patients and a review of the literature. Cancer. 1996;77(11):2400–2.PubMedCrossRef

102.

103.

Buehler D, Rice SR, Moody JS, et al. Angiosarcoma outcomes and prognostic factors: a 25-year single institution experience. Am J Clin Oncol. 2014;37(5):473–9. https://doi.org/10.1097/COC.0b013e31827e4e7b.CrossRefPubMedPubMedCentral

104.

Fayette J, Martin E, Piperno-Neumann S, et al. Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol. 2007;18(12):2030–6. https://doi.org/10.1093/annonc/mdm381.CrossRefPubMed

105.

Naka N, Ohsawa M, Tomita Y, et al. Prognostic factors in angiosarcoma: a multivariate analysis of 55 cases. J Surg Oncol. 1996;61(3):170–6. https://doi.org/10.1002/(SICI)1096-9098(199603)61:3%3c170::AID-JSO2%3e3.0.CO;2-8.CrossRefPubMed

106.

Oxenberg J, Khushalani NI, Salerno KE, Attwood K, Kane JM. Neoadjuvant chemotherapy for primary cutaneous/soft tissue angiosarcoma: determining tumor behavior prior to surgical resection. J Surg Oncol. 2015;111(7):829–33. https://doi.org/10.1002/jso.23891.CrossRefPubMed

107.

Conforti F, Gronchi A, Penel N, et al. Chemotherapy in patients with localized angiosarcoma of any site: a retrospective European study. Eur J Cancer. 2022;171:183–92.PubMedCrossRef

108.

Palassini E, Baldi GG, Sulfaro S, et al. Clinical recommendations for treatment of localized angiosarcoma: a consensus paper by the Italian Sarcoma Group. Cancer Treatment Reviews. 2024;126:102722.PubMedCrossRef

109.

Gronchi A, Miceli R, Shurell E, et al. Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets. J Clin Oncol. 2013;31(13):1649–55.PubMedCrossRef

110.

Peacock O, Patel S, Simpson JA, Walter CJ, Humes DJ. A systematic review of population-based studies examining outcomes in primary retroperitoneal sarcoma surgery. Surgical Oncology. 2019;29:53–63.PubMedCrossRef

111.

Callegaro D, Fiore M, Gronchi A. Personalizing surgical margins in retroperitoneal sarcomas. Expert Rev Anticancer Therapy. 2015;15(5):553–67.CrossRef

112.

Toulmonde M, Bonvalot S, Méeus P, et al. Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. Ann Oncol. 2014;25(3):735–42.PubMedPubMedCentralCrossRef

113.

Brown RE, St Hill CR, Greene QJ, et al. Impact of histology on survival in retroperitoneal sarcomas. Am J Surg. 2011;202(6):748–52.PubMedCrossRef

114.

Anaya DA, Lahat G, Wang X, et al. Establishing prognosis in retroperitoneal sarcoma: a new histology-based paradigm. Ann Surg Oncol. 2009;16(3):667–75.PubMedCrossRef

115.

Singer S, Antonescu CR, Riedel E, Brennan MF. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg. 2003;238(3):358–70.PubMedPubMedCentralCrossRef

116.

Lahat G, Anaya DA, Wang X, Tuvin D, Lev D, Pollock RE. Resectable well-differentiated versus dedifferentiated liposarcomas: two different diseases possibly requiring different treatment approaches. Ann Surg Oncol. 2008;15(6):1585–93.PubMedCrossRef

117.

Dingley B, Fiore M, Gronchi A. Personalizing surgical margins in retroperitoneal sarcomas: an update. Expert Rev Anticancer Ther. 2019;19(7):613–31.PubMedCrossRef

118.

Anaya DA, Lev DC, Pollock RE. The role of surgical margin status in retroperitoneal sarcoma. J Surg Oncol. 2008;98(8):607–10.PubMedCrossRef

119.

Kirane A, Crago AM. The importance of surgical margins in retroperitoneal sarcoma. J Surg Oncol. 2016;113(3):270–6.PubMedCrossRef

120.

Abdelfatah E, Guzzetta AA, Nagarajan N, et al. Long-term outcomes in treatment of retroperitoneal sarcomas: A 15 year single-institution evaluation of prognostic features. J Surg Oncol. 2016;114(1):56–64.PubMedPubMedCentralCrossRef

121.

Khan S, Ng D, Koerber D, et al. Is microscopic margin status important in retroperitoneal sarcoma (RPS) resection? A systematic review and metaanalysis. Can J Surg. 2022;6(Suppl 2):65.

122.

Bonvalot S, Rivoire M, Castaing M, et al. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. J Clin Oncol. 2009;27(1):31–7.PubMedCrossRef

123.

Stahl JM, Corso CD, Park HS, et al. The effect of microscopic margin status on survival in adult retroperitoneal soft tissue sarcomas. Eur J Surg Oncol. 2017;43(1):168–74.PubMedCrossRef

124.

Gronchi A, Miceli R, Colombo C, et al. Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas. Ann Oncol. 2012;23(4):1067–73.PubMedCrossRef

125.

Bonvalot S, Miceli R, Berselli M, et al. Aggressive surgery in retroperitoneal soft tissue sarcoma carried out at high volume centers is safe and is associated with improved local control. Ann Surg Oncol. 2010;17:1507–14.PubMedCrossRef

126.

Bonvalot S, Gronchi A, Le Péchoux C, et al. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21(10):1366–77.PubMedCrossRef

127.

Callegaro D, Raut CP, Ajayi T, et al. Preoperative Radiotherapy in Patients With Primary Retroperitoneal Sarcoma: EORTC-62092 Trial (STRASS) Versus Off-trial (STREXIT) Results. Ann Surg. 2023;278(1):127–34.PubMedCrossRef

128.

Gervais MK, Callegaro D, Gronchi A. The evolution of adjuvant/neoadjuvant trials for resectable localized sarcoma. J Surg Oncol. 2022;125(1):17–27.PubMedCrossRef

129.

Mussi C, Collini P, Miceli R, et al. The prognostic impact of dedifferentiation in retroperitoneal liposarcoma: a series of surgically treated patients at a single institution. Cancer. 2008;113(7):1657–65.PubMedCrossRef

130.

Keung EZ, Hornick JL, Bertagnolli MM, Baldini EH, Raut CP. Predictors of outcomes in patients with primary retroperitoneal dedifferentiated liposarcoma undergoing surgery. J Am Coll Surg. 2014;218(2):206–17.PubMedCrossRef

131.

Jour G, Gullet A, Liu M, Hoch BL. Prognostic relevance of Fédération Nationale des Centres de Lutte Contre le Cancer grade and MDM2 amplification levels in dedifferentiated liposarcoma: a study of 50 cases. Mod Pathol. 2015;28(1):37–47.PubMedCrossRef

132.

Thway K. Well-differentiated liposarcoma and dedifferentiated liposarcoma: an updated review. Sem Diagn Pathol. 2019;36(2):112–21.CrossRef

133.

Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573–81.PubMedCrossRef

134.

Bonvalot S, Roland C, Raut C, et al. Histology-tailored multidisciplinary management of primary retroperitoneal sarcomas. Eur J Surg Oncol. 2023;49:1061–7.PubMedCrossRef

135.

Tzanis D, Bouhadiba T, Gaignard E, Bonvalot S. Major vascular resections in retroperitoneal sarcoma. J Surg Oncol. 2018;117(1):42e7.CrossRef

136.

Fiore M, Colombo C, Locati P, et al. Surgical technique, morbidity, and outcome of primary retroperitoneal sarcoma involving inferior vena cava. Ann Surg Oncol. 2012;19(2):5118.CrossRef

137.

Demetri GD, Chawla SP, von Mehren M, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009;27:4188–96.PubMedCrossRef

138.

D’Ambrosio L, Touati N, Blay JY, et al. Doxorubicin plus dacarbazine (DoDa), doxorubicin plus ifosfamide (DI) or doxorubicin alone (Do) as first line treatment for advanced leiomyosarcoma (LMS): a retrospective study from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) [abstract]. J Clin Oncol. 2018;36:11574.CrossRef

139.

Friis RB, Safwat A, Baad-Hansen T, Aggerholm-Pedersen N. Solitary fibrous tumour: a single institution retrospective study and further validation of a prognostic risk assessment system. Clin Oncol. 2018;30(12):798–804.CrossRef

140.

Kallen ME, Hornick JL. The 2020 WHO classification: what’s new in soft tissue tumor pathology? Am J Surg Pathol. 2021;45(1):e1-23.PubMedCrossRef

141.

Thway K, Ng W, Noujaim J, Jones RL, Fisher C. The current status of solitary fibrous tumor: diagnostic features, variants, and genetics. Int J Surg Pathol. 2016;24(4):281–92.PubMedCrossRef

142.

Demicco EG, Park MS, Araujo DM, et al. Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model. Mod Pathol. 2012;25(9):1298–306.PubMedCrossRef

143.

Salas S, Resseguier N, Blay JY, et al. Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database. Ann Oncol. 2017;28(8):1979–87.PubMedCrossRef

144.

Martin-Broto J, Cruz J, Penel N, et al. Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21(3):456–66.PubMedCrossRef

145.

Vauthey JN, Woodruff JM, Brennan MF. Extremity malignant peripheral nerve sheath tumors (neurogenic sarcomas): a 10-year experience. Ann Surg Oncol. 1995;2:126–31.PubMedCrossRef

146.

Stucky CC, Johnson KN, Gray RJ, et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann Surg Oncol. 2012;19:878–85.PubMedCrossRef

147.

Upadhyaya M, Spurlock G, Monem B, et al. Germline and somatic NF1 gene mutations in plexiform neurofibromas. Hum Mutat. 2008;29:E103–11.PubMedCrossRef

148.

Miettinen MM, Antonescu CR, Fletcher CDM, et al. Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1—a consensus overview. Hum Pathol. 2017;67:1–10.PubMedPubMedCentralCrossRef

149.

Yao C, Zhou H, Dong Y, et al. Malignant peripheral nerve sheath tumors: latest concepts in pathogenesis and clinical management. Cancers. 2023;15:1077-1–19.CrossRef

150.

Zehou O, Fabre E, Zelek L, et al. Chemotherapy for the treatment of malignant peripheral nerve sheath tumors in neurofibromatosis 1: a 10-year institutional review. Orphanet J Rare Dis. 2013;8:127.PubMedPubMedCentralCrossRef

151.

Kolberg M, Holand M, Agesen TH, et al. Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro Oncol. 2013;15:135–47.PubMedCrossRef

152.

Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19:1238–47.PubMedCrossRef

153.

Kroep JR, Ouali M, Gelderblom H, et al. First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histologic soft tissue sarcoma (STS) subtypes and as a prognostic factor for MPNST: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) study. J Clin Oncol. 2010. https://doi.org/10.1200/jco.2010.28.15_suppl.1007.CrossRef

154.

Higham CS, Steinberg SM, Dombi E, et al. SARC006: phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 associated chemotherapy naive malignant peripheral nerve sheath tumors. Sarcoma. 2017;1:8685638.

155.

Wong WW, Hirose T, Scheithauer BW, Schild SE, Gunderson LL. Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys. 1998;42:351–60.PubMedCrossRef

156.

Pisters PW, Harrison LB, Leung DH, Woodruff JM, Casper ES, Brennan MF. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol. 1996;14:859–68.PubMedCrossRef

157.

Tseng WW, Barretta F, Conti L, et al. Defining the role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma: a multi-institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. Cancer. 2021;127(5):729e73.CrossRef

Titel: Histology-Tailored Approach to Soft Tissue Sarcoma
verfasst von: Mai-Kim Gervais, MD
Georges Basile, MD
Jean-Philippe Dulude, MD
Sophie Mottard, MD
Alessandro Gronchi, MD
Publikationsdatum: 22.08.2024
Verlag: Springer International Publishing
Erschienen in: Annals of Surgical Oncology / Ausgabe 12/2024
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-024-15981-8

Disparate Tumor Characteristics and Survival Outcomes Between Squamous Cell and Adenocarcinoma Subtypes in Cholangiocarcinoma

Hepatobiliary Tumors

Surgical Outcome After Distal Pancreatectomy With and Without Portomesenteric Venous Resection in Patients with Pancreatic Adenocarcinoma: A Transatlantic Evaluation of Patients in North America, Germany, Sweden, and The Netherlands (GAPASURG)

Open Access
Pancreatic Tumors

ASO Visual Abstract: Persistent Pain After Breast Cancer Treatment, an Underreported Burden for Breast Cancer Survivors

ASO Visual Abstract

Development of a Novel Protocol for Germline Testing in Pancreatic Cancer

Translational Research

Evaluating the Effect of MarginProbe® Use on Re-excisions After Partial Mastectomy: A Single-Institution Analysis

Breast Oncology

Minimally Invasive Left Hepatectomy: Choosing the Suitable Surgical Strategy

Hepatobiliary Tumors

Neu im Fachgebiet Chirurgie

Welcher Zugangsweg ist besser für den interventionellen Mitralklappenersatz?

29.04.2025
DGK-Jahrestagung 2025
Kongressbericht

Bisher wird für den interventionellen Mitralklappenersatz standardmäßig der transapikale Zugangsweg gewählt. In einer Registeranalyse hat dieser in puncto Sicherheit allerdings den Kürzeren gezogen.

Lohnt sich die Karotis-Revaskularisation?

25.04.2025
Karotisstenose
Nachrichten

Die medikamentöse Therapie für Menschen mit Karotisstenosen hat sich in den vergangenen Dekaden verbessert. Braucht es also noch einen invasiven Eingriff zur Revaskularisation der Halsschlagader bei geringem bis moderatem Risiko für einen ipsilateralen Schlaganfall?

Höhere Dosis von Dexamethason senkt Überlebenschancen

25.04.2025
Zerebrale Metastasen
Nachrichten

Personen mit Hirnmetastasen, die perioperativ höhere kumulative Dosen von Dexamethason erhalten, haben eine schlechtere Prognose. Um die Ergebnisse zu verbessern, bedarf es strengerer Dosierungsschemata.

Appendektomie erhält Remission bei Colitis ulcerosa

24.04.2025
Colitis ulcerosa
Nachrichten

Wird der Wurmfortsatz bei Personen mit Colitis ulcerosa entfernt, ist die Rückfallrate um ein Drittel geringer als unter konservativer Behandlung. Auch die Lebensqualität verbessert sich und der Bedarf an Medikamenten nimmt ab.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Histology-Tailored Approach to Soft Tissue Sarcoma

Abstract

Weitere Artikel der Ausgabe 12/2024

Disparate Tumor Characteristics and Survival Outcomes Between Squamous Cell and Adenocarcinoma Subtypes in Cholangiocarcinoma

Surgical Outcome After Distal Pancreatectomy With and Without Portomesenteric Venous Resection in Patients with Pancreatic Adenocarcinoma: A Transatlantic Evaluation of Patients in North America, Germany, Sweden, and The Netherlands (GAPASURG)

ASO Visual Abstract: Persistent Pain After Breast Cancer Treatment, an Underreported Burden for Breast Cancer Survivors

Development of a Novel Protocol for Germline Testing in Pancreatic Cancer

Evaluating the Effect of MarginProbe® Use on Re-excisions After Partial Mastectomy: A Single-Institution Analysis

Minimally Invasive Left Hepatectomy: Choosing the Suitable Surgical Strategy

Neu im Fachgebiet Chirurgie

Welcher Zugangsweg ist besser für den interventionellen Mitralklappenersatz?

Lohnt sich die Karotis-Revaskularisation?

Höhere Dosis von Dexamethason senkt Überlebenschancen

Appendektomie erhält Remission bei Colitis ulcerosa

Update Chirurgie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten